You are here: Industry Insights > Editas Medicine

News List

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting firstwordpharma
August 23, 2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced data on a new gene editing technologytermed SLEEK (SeLection by Essential-gene Exon Knock-in).
CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData expresspharma
March 15, 2021
Three leading companies racing to bring CRISPR therapies to the clinic are CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.
Catalent Partners with Gene Editing Company Editas contractpharma
July 30, 2020
Will provide services for the development and manufacturing of Editas’ cell and gene medicines.
Editas Medicine shares fall over 20 percent on departure of CEO firstwordpharma
January 23, 2019
Editas Medicine said Tuesday that CEO Katrine Bosley has decided to step down from her role effective March 1, with board member Cynthia Collins appointed to the position on an interim basis.
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
December 03, 2018
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
December 02, 2018
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10).
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
December 02, 2018
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10).
CRISPR biotech Editas to lose CMO as it continues push for clinical trials fiercebiotech
August 29, 2018
Editas is now looking for a new CMO as it also plots its first clinical trials